---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066403"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:41:01.791723+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track

## Summary
- Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.
- Cash, cash equivalents and marketable securities $707.1M as of March 31, 2025, down from $861.7M at Dec 31, 2024; expected to fund operations into H1 2027.
- Phase 3 HAELO study for hereditary angioedema on track to complete enrollment in Q3 2025; BLA submission anticipated in H2 2026.
- First patient dosed in Phase 3 MAGNITUDE-2 for ATTRv-PN; MAGNITUDE (ATTR-CM) enrollment ahead of projections.
- RMAT designation granted for nex-z in ATTR-CM; longer-term Phase 1 data presentations planned for H2 2025.

## SEC filing metadata
- accession: 0000950170-25-066403
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/0000950170-25-066403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/ntla-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066403
- JSON: https://secwatch.observer/filing/0000950170-25-066403.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.